LIPELLA PHARMACEUTICALS INC. (LIPO)

SEC fundamentals · as filed in 10-Q FY2025, period ended Sep 30, 2025 · updated Oct 7, 2026

Verified against EDGAR
Total Assets
$2.3M
Stockholders' Equity
$1.5M
Cash & Equivalents
$1.9M
Long-Term Debt
—

as filed in 10-Q FY2025, period ended Sep 30, 2025 · View filings on EDGAR ↗

In its 10-Q for the period ended Sep 30, 2025, LIPELLA PHARMACEUTICALS INC. reported revenue of $0, net income of -$1.3M, and total assets of $2.3M. Every figure below is taken directly from LIPELLA PHARMACEUTICALS INC.'s SEC filings: each links to the source document on EDGAR.

Revenue trend

Revenue · FY2021–FY2024 · as reported

$536,357-$2.2M-$5.0M
FY2021FY2022FY2023FY2024
Revenue$536,357Net income-$5.0M
FY2021 revenue
$259,347
FY2024 revenue
$536,357

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2024$536,357-$5.0M
FY2023$449,617-$4.6M
FY2022$184,156-$2.6M
FY2021$259,347-$1.9M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KJul 15, 2026on EDGAR ↗
8-KMar 31, 2026on EDGAR ↗
8-KFeb 4, 2026on EDGAR ↗
10-QNov 14, 2025on EDGAR ↗
8-KOct 21, 2025on EDGAR ↗
8-KOct 9, 2025on EDGAR ↗
8-KSep 18, 2025on EDGAR ↗
10-QAug 14, 2025on EDGAR ↗
8-KJun 25, 2025on EDGAR ↗
8-KJun 20, 2025on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Sep 30, 2025 · 10-Q

Total Assets$2.3Msource ↗
Stockholders’ Equity$1.5Msource ↗
Cash & Equivalents$1.9Msource ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Sep 30, 2025

Revenue$0source ↗
Net Income-$1.3Msource ↗
Operating Income-$1.3Msource ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$720,973source ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Sep 30, 2025

EPS (diluted)$-0.28source ↗
EPS (basic)$-0.28source ↗
Shares Outstanding4.6Msource ↗
Cash from Operations-$926,057source ↗
Cash from Financing$0source ↗
Cash from Investing—source ↗

Restatement history

Point-in-time

No material restatements detected across 97 annual fact-keys: this company's as-filed numbers have held between filings. Point-in-time and as-of history are available via the API.

Deeper fundamentals

A free API key reaches LIPO’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Get a free API key →See plans

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/LIPO

MCP tool: get_sec_fundamentals ticker=LIPO

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/LIPO/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=LIPO as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/LIPO/history

MCP tool: get_fundamentals_history ticker=LIPO

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/financial-health/LIPO

MCP tool: get_financial_health ticker=LIPO

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.